{"id":"imovax-polio-inactivated-poliomyelitis-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated poliovirus serotypes 1, 2, and 3, which cannot cause disease but trigger a humoral immune response. B cells recognize the viral antigens and produce neutralizing antibodies that protect against infection if the vaccinated person is exposed to wild-type poliovirus. This provides long-lasting immunity through antibody-mediated protection without the risk of vaccine-derived poliovirus.","oneSentence":"IMOVAX Polio stimulates the immune system to produce antibodies against all three poliovirus types by introducing inactivated (killed) poliovirus particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:22.754Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3"}]},"trialDetails":[{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT00258843","phase":"PHASE3","title":"Safety of Imovax Polio in Chinese Infants and Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-11","conditions":"Poliomyelitis","enrollment":40},{"nctId":"NCT00348387","phase":"PHASE3","title":"Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Poliomyelitis, Polio","enrollment":600},{"nctId":"NCT01278433","phase":"PHASE4","title":"A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-12","conditions":"Polio, Poliomyelitis","enrollment":5007},{"nctId":"NCT01244464","phase":"PHASE4","title":"A Study of the Safety of IMOVAX Polio™ in China","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Poliomyelitis, Polio","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IMOVAX Polio™"],"phase":"marketed","status":"active","brandName":"IMOVAX Polio™: Inactivated Poliomyelitis Vaccine","genericName":"IMOVAX Polio™: Inactivated Poliomyelitis Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"IMOVAX Polio stimulates the immune system to produce antibodies against all three poliovirus types by introducing inactivated (killed) poliovirus particles. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}